Alpha Cognition Inc. Common Stock (ACOG) Stock

Alpha Cognition Inc. Common Stock (ACOG) is a Healthcare stock trading at $6.89 (as of 2026-06-18), with a market capitalization of $132.39M and a trailing P/E of -4.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Alpha Cognition Inc. is a clinical-stage biopharmaceutical company developing therapies for Alzheimer’s disease and ALS. Its programs include ZUNVEYL (benzgalantamine) for mild-to-moderate Alzheimer’s disease and mild traumatic brain injury, ALPHA-0602 gene therapy for ALS, and ALPHA-0702 and ALPHA-0802 for neurodegenerative diseases.

Valuation — source: SEC EDGAR (first-party)
Price	$6.89
Market Cap	$132.39M
P/E Ratio	-4.4
EV / EBITDA	-2.8
Price / Book	2.27
Price / Sales	12.05
DCF Value (model)	$-13.13
DCF Upside vs Price	-290.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$10.22M
Net Margin	-202.2%
Return on Equity	-43.8%
Current Ratio	12.64
Revenue Growth (YoY)	20.7%
EPS Growth (YoY)	130.8%
FCF Growth (YoY)	459.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	3.77 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.4
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-120.9%
vs Industry	-125.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Opaleye Management Inc. ($14.07M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Michael E. McFadden
Employees	5
Country	CA
IPO Date	2025-03-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.